- Sections
- C - Chimie; métallurgie
- C07K - Peptides
- C07K 14/81 - Inhibiteurs de protéase
Détention brevets de la classe C07K 14/81
Brevets de cette classe: 1126
Historique des publications depuis 10 ans
|
77
|
85
|
101
|
81
|
86
|
102
|
110
|
91
|
74
|
22
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Immatics Biotechnologies GmbH | 1144 |
35 |
| Angiochem Inc. | 50 |
29 |
| Takeda Pharmaceutical Company Limited | 2961 |
23 |
| Daiichi Sankyo Company, Limited | 1829 |
18 |
| The Regents of the University of California | 18943 |
17 |
| Translate bio, Inc. | 394 |
17 |
| Avacta Life Sciences Limited | 29 |
15 |
| CSL Behring GmbH | 350 |
14 |
| Cytonics Corporation | 23 |
14 |
| Inhibrx, Inc. | 134 |
13 |
| Biotissue Holdings Inc. | 49 |
12 |
| Genentech, Inc. | 3742 |
11 |
| ProThera Biologics, Inc. | 23 |
10 |
| Serpin Pharma, LLC | 17 |
10 |
| The Board of Trustees of the Leland Stanford Junior University | 6054 |
9 |
| Amgen Inc. | 3779 |
8 |
| 3B Pharmaceuticals GmbH | 35 |
8 |
| Omeros Corporation | 286 |
8 |
| Alteogen Inc. | 56 |
7 |
| The Regents of the University of Colorado, a body corporate | 2430 |
7 |
| Autres propriétaires | 841 |